The best competitive intelligence tools for biotech in 2026
Biotech CI today is mostly conference notes, a Cortellis tab, and someone who "just knows the space." When the strategy that comes out of it steers a nine-figure program, "someone just knows" isn't a data source. Ranked for competitor moves you can actually open (clearances, approvals, refusals, designations), with deals and IP called out as the different buy they are.
How biotech CI actually gets done
Here's the uncomfortable mechanism behind most biotech CI: an expert casts a wide net, reads what they have time to read, and extrapolates the rest from experience. That's not laziness — the public record is enormous, scattered across dozens of authority databases, and much of it is scanned PDF a human can't skim at scale. But the output is expertise-shaped guesswork wearing a data costume, and everyone in the room quietly knows it.
The thing is, competitive intelligence in this industry is a nearly perfect AI problem: the moves that matter (what cleared, what got refused, what designation was granted, what the reviewer accepted) are all public. You need a huge net and the patience to read everything in it. That's precisely what agents are for, and it's the bar this ranking scores against.
Methodology & scoring
Facts from public materials as of August 2026. Deals/IP/pipeline depth is noted but not the main score — that's a different product category, and big commercial-data estates (IQVIA-class) are a different buy again. Failed programs count double here: negative precedent (trials that missed, applications that were refused) is some of the most decision-relevant CI there is, and the hardest to find by hand.
- Coverage of public regulatory moves (clearances, approvals, refusals, designations)
- Traceability — can you open the underlying document?
- AI / askability — can a non-power-user get an answer?
- Speed to something usable in a Monday meeting
- Price transparency
Ranked for biotech CI workflows
Rhizome AI
Best for cited competitor moves from the public recordRhizome is a focused, AI regulatory coworker, and CI is one of the places that focus pays off most. Ask "what have the last 30 products in this class done about this endpoint?" and the agents fan out across the record (>45 million documents spanning >75 health-authority databases and >12 markets as of August 2026) and come back with a synthesized answer carrying up to 1,000 citations, each one opening to the exact passage. That includes the negative precedent a human search almost never surfaces: the failed trials, the refusals, the products approved despite missed endpoints.
Nothing in an answer comes from model memory; we benchmark our agents on that. So when the CI deck says a competitor's device cleared with a specific study design, the claim opens to the clearance itself. Free tier, published pricing; connects into Claude/ChatGPT/Copilot over MCP.
Cortellis Competitive Intelligence (+ Deals, if you buy it)
Best traditional CI suiteIf your CI function needs pipeline context, partnering activity, and deal terms in one place, Cortellis's curated breadth is the established answer, and for portfolio/BD teams that breadth is the product. It's also a genuinely different job than precedent CI, which is why plenty of teams run both.
The limits are the familiar curated-suite ones: enterprise custom pricing, and answers assembled from analyst summaries rather than the underlying filings — fine for landscape, thinner when you need to know exactly what a reviewer accepted and why.
General AI alone (ChatGPT, Claude, Gemini, Copilot)
Fast landscape sketches; verify before the deckAlready paid for, instantly askable, and genuinely useful for orienting on a competitor you've never looked at. The structural catch: general assistants answer from memory plus the open web, and the moves that matter live in authority databases a crawler mostly can't see. So you get the famous cases and the press-covered approvals, a thin slice of what's out there, with citations that don't reliably survive the click. Copilot adds its own twist: grounded in your tenant, it hands you your own documents back when the question is about the world outside.
Keep whichever one your team likes and connect Rhizome over MCP; the assistant stays the shell, the grounded scan runs behind it.
In-house AI (internal bots on public filings)
The build path, for when CI is truly your edgeSome funds and BD-heavy companies treat their analytical machinery as the moat, and for them building can be right. For everyone else, the math is the same as in regulatory: the corpus maintenance, OCR, refresh, and evaluation are the product, they cost engineering salaries forever, and a snapshot corpus produces confident answers with invisible gaps. Build AI where it differentiates you; competitor clearance histories are the same public record for everyone.
DIY (ClinicalTrials.gov + FDA databases + Google)
Free baselineEverything's public and the price is right. The cost is your evenings: every database has its own search grammar, none of them synthesize, and the interesting answer is usually spread across four of them. Fine in thrift mode; the first missed competitor move pays for a real tool.
Matching the tool to the question
Leveraged by large pharma, independent consultants, and everyone in between
“Last time we did this research, we spent weeks. Rhizome found the answer immediately.”
“Chetan idk what kind of magic you all did here, it's so good!”
“I want this. I'm really impressed by the quality of the information and the level of detail.”